KIT Mutations and Other Genetic Defects in Mastocytosis: Implications for Disease Pathology and Targeted Therapies

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Systemic mastocytosis (SM) is a myeloid neoplasm characterized by mast cell accumulation.
• The KIT D816V activating mutation is present in over 90% of indolent SM cases.
• Advanced SM variants can harbor additional genetic mutations in myeloid malignancy-related genes.

Purpose of the Study:

• To review current diagnostic and monitoring techniques for KIT D816V mutations in SM.
• To highlight the role of next-generation sequencing in identifying additional genetic defects in advanced SM.
• To emphasize the utility of PCR-based methods for mutational burden quantification.

Main Methods:

• Detection of KIT D816V mutation using allele-specific quantitative PCR (AS-qPCR).
• Quantification of KIT D816V mutational burden via droplet digital PCR (ddPCR).
• Application of next-generation sequencing (NGS) for identifying additional genetic alterations.

Main Results:

• KIT D816V mutation is a hallmark of indolent SM, found in >90% of patients.
• Advanced SM may present with concurrent mutations in other myeloid malignancy genes.
• AS-qPCR and ddPCR are established methods for KIT D816V detection and quantification.
• NGS enables comprehensive genetic profiling in advanced SM.

Conclusions:

• KIT D816V mutation detection is crucial for SM diagnosis.
• Quantitative PCR techniques are vital for monitoring disease burden and treatment response.
• Next-generation sequencing provides deeper genetic insights into advanced SM subtypes.
• Accurate molecular diagnostics facilitate personalized treatment strategies for SM patients.